Angela Constance Garinis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Angela Constance Garinis has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Dawn Konrad-Martin
Veterans Health Administration (VA) Rehabilitation Research and Development (RR&D), National Center for Rehabilitative Auditory Research, VA Portland Health Care System, OR
4 shared publicationsLisa L. Hunter
Cincinnati Children’s Hospital Medical Center, Communication Sciences Research Center, Cincinnati, Ohio, USA
4 shared publicationsDaniel B. Putterman
VA Rehabilitation Research Development and Translation, National Center for Rehabilitative Auditory Research, VA Portland Health Care System, Portland, Oregon, USA
3 shared publicationsDouglas H. Keefe
Boys Town National Research Hospital, Omaha, Nebraska, USA
3 shared publicationsM. Patrick Feeney
VA Rehabilitation Research Development and Translation, National Center for Rehabilitative Auditory Research, VA Portland Health Care System, Portland, Oregon, USA
3 shared publications- Peter S. Steyger
Bellucci Translational Hearing Center, Department of Biomedical Sciences, Creighton University School of Medicine, 2500 California Plaza, Omaha, NE 68178, USA
3 shared publications
Latest Publications
- 30 June 2025
- Published by Wolters Kluwer Health in Ear & Hearing
- Vol. 46 (6) , 1584-1594
Wideband Middle-Ear Measures in Aminoglycoside-Exposed Adults with Cystic Fibrosis
Objectives: Cystic fibrosis (CF) affects sinus and lung function, yet little is known about middle-ear function in relation to disease severity. Wideband (WB) absorbance measures are a more sensitive and specific metric of middle-ear function than traditional, single-frequency tympanometry. WB tympanometric measures were used to study middle-ear function in normal-hearing persons with CF and varying degrees of exposure to intravenous aminoglycoside (IV-AG) antibiotics as a proxy for disease severity compared with age-matched persons without CF. Methods: Middle-ear function was assessed in normal-hearing adult participants with (N = 57) and without CF (N = 29). Four groups were examined: (1) CF with a history of greater than 40 doses of IV-AGs (CF high IV-AG), (2) CF with fewer than 40 doses of IV-AGs (CF low IV-AG), (3) CF with no previous IV-AG exposures (CF no IV-AG), and (4) Healthy controls without CF or history of IV-AG exposure (non-CF). Clinical tests included pure-tone air (250 to 8000 Hz) and bone conduction audiometry (250 to 4000 Hz) and 226 Hz tympanometry. Experimental WB downswept tympanometry was also conducted for 250 to 8000 Hz. Hearing thresholds, air-bone gaps, and 226 Hz static acoustic admittance were compared between groups. WB tympanometric absorbance and peak-to-tail differences were compared between groups at half-octave frequencies, as was the tympanometric width (TW) of the low-frequency averaged absorbance tympanogram (from 380 to 2000 Hz) around its tympanometric peak pressure. Results: Air conduction thresholds were elevated for patients with CF for 250 to 2000 Hz compared with control participants. Broader absorbance TW was found for the CF participants relative to the non-CF control participants (p < 0.05). Specifically, non-CF controls demonstrated smaller TW compared with the CF no IV-AG (p = 0.015), CF low IV-AG (p = 0.011), and CF high IV-AG (p < 0.001) groups. WB peak-to-tail differences further revealed statistically significant group mean differences between the CF no IV-AG and CF high IV-AG groups from 500 to 1000 Hz (p < 0.05) and non-CF controls and CF high IV-AG group at 2000 and 5660 Hz (p < 0.05). There were no statistically significant differences at the p < 0.05 level for mean static acoustic admittance (Y tm) obtained from the 226 Hz tympanogram between non-CF controls and the three CF IV-AG exposure groups (p = 0.076). Conclusions: Novel findings from this investigation revealed that participants with CF regardless of AG dosing had greater WB TW compared with non-CF controls. Greater WB TW along with poorer (elevated) low-frequency audiometric thresholds and lower absorbance peak-to-tail differences compared with non-CF controls suggest increased middle-ear stiffness in individuals with CF. These differences are subtle as reflected in the higher air conduction thresholds at low frequencies, despite absent air-bone gaps. Additional studies of middle-ear function in CF patients with a history of middle-ear disorders are needed to determine the clinical implications of these findings.
- 30 June 2025
- Published by Wolters Kluwer Health in Ear & Hearing
- Vol. 46 (6) , 1584-1594
Wideband Middle-Ear Measures in Aminoglycoside-Exposed Adults with Cystic Fibrosis
Objectives: Cystic fibrosis (CF) affects sinus and lung function, yet little is known about middle-ear function in relation to disease severity. Wideband (WB) absorbance measures are a more sensitive and specific metric of middle-ear function than traditional, single-frequency tympanometry. WB tympanometric measures were used to study middle-ear function in normal-hearing persons with CF and varying degrees of exposure to intravenous aminoglycoside (IV-AG) antibiotics as a proxy for disease severity compared with age-matched persons without CF. Methods: Middle-ear function was assessed in normal-hearing adult participants with (N = 57) and without CF (N = 29). Four groups were examined: (1) CF with a history of greater than 40 doses of IV-AGs (CF high IV-AG), (2) CF with fewer than 40 doses of IV-AGs (CF low IV-AG), (3) CF with no previous IV-AG exposures (CF no IV-AG), and (4) Healthy controls without CF or history of IV-AG exposure (non-CF). Clinical tests included pure-tone air (250 to 8000 Hz) and bone conduction audiometry (250 to 4000 Hz) and 226 Hz tympanometry. Experimental WB downswept tympanometry was also conducted for 250 to 8000 Hz. Hearing thresholds, air-bone gaps, and 226 Hz static acoustic admittance were compared between groups. WB tympanometric absorbance and peak-to-tail differences were compared between groups at half-octave frequencies, as was the tympanometric width (TW) of the low-frequency averaged absorbance tympanogram (from 380 to 2000 Hz) around its tympanometric peak pressure. Results: Air conduction thresholds were elevated for patients with CF for 250 to 2000 Hz compared with control participants. Broader absorbance TW was found for the CF participants relative to the non-CF control participants (p < 0.05). Specifically, non-CF controls demonstrated smaller TW compared with the CF no IV-AG (p = 0.015), CF low IV-AG (p = 0.011), and CF high IV-AG (p < 0.001) groups. WB peak-to-tail differences further revealed statistically significant group mean differences between the CF no IV-AG and CF high IV-AG groups from 500 to 1000 Hz (p < 0.05) and non-CF controls and CF high IV-AG group at 2000 and 5660 Hz (p < 0.05). There were no statistically significant differences at the p < 0.05 level for mean static acoustic admittance (Y tm) obtained from the 226 Hz tympanogram between non-CF controls and the three CF IV-AG exposure groups (p = 0.076). Conclusions: Novel findings from this investigation revealed that participants with CF regardless of AG dosing had greater WB TW compared with non-CF controls. Greater WB TW along with poorer (elevated) low-frequency audiometric thresholds and lower absorbance peak-to-tail differences compared with non-CF controls suggest increased middle-ear stiffness in individuals with CF. These differences are subtle as reflected in the higher air conduction thresholds at low frequencies, despite absent air-bone gaps. Additional studies of middle-ear function in CF patients with a history of middle-ear disorders are needed to determine the clinical implications of these findings.
- 4 March 2024
- Published by American Speech Language Hearing Association in American Journal of Audiology
- Vol. 33 (1) , 283-291
Clinical Observations in Patients With Cystic Fibrosis–Related Diabetes and Self-Reported Ototoxicity Symptoms
Purpose: Persons with cystic fibrosis (PwCF) are at high risk for ototoxicity due to the routine use of intravenous aminoglycoside (IV-AG) antibiotics in respiratory infection management. Additionally, factors that contribute to ototoxicity-related symptom development and severity in PwCF are unknown. Given the increased risk of ototoxicity in people with diabetes, we explored the association between cystic fibrosis–related diabetes (CFRD) and self-reported ototoxicity symptoms (tinnitus and vestibular problems) in PwCF treated with aminoglycosides. Method: PwCF ( N = 39; 25 females, 14 males; M age = 30.1 years, SD = 10.3) were recruited from the Cystic Fibrosis Care Center at Oregon Health & Science University. Patients completed the validated questionnaires to ascertain their experiences with ototoxicity-related symptoms of tinnitus and balance function. The diagnosis of CFRD, including oral glucose tolerance testing (OGTT), insulin treatment, hemoglobin A1c, and cumulative IV-AG treatment history, was obtained through a medical chart review. Participants were classified into three groups based on their medical diagnoses via OGTT: normal glucose tolerance (NGT; control; n = 16), abnormal glucose tolerance (AGT; n = 9), and CFRD ( n = 14). Participants in each group were further classified based on survey outcomes for ototoxicity-related symptoms. Results: There was a trend toward a higher proportion of patients with CFRD reporting tinnitus compared to the AGT and NGT groups, but did not meet statistical significance ( X 2 = 2.24, p = .13). Approximately, 43% of patients with CFRD reported experiencing clinically significant tinnitus lasting > 3 min compared to 11% in the AGT group and 13% in the NGT group ( X 2 = 3.751, p = .05). Cumulative IV-AG exposure tended to be higher in CFRD compared to other groups. High balance function was generally reported in all groups. Conclusions: Patients with CFRD have greater ototoxicity-related symptoms. Further investigation of the relationship between CF-related comorbidities and the risk of developing ototoxicity-related symptoms is warranted to improve the detection and management of ototoxicity in PwCF.
- 4 March 2024
- Published by American Speech Language Hearing Association in American Journal of Audiology
- Vol. 33 (1) , 283-291
Clinical Observations in Patients With Cystic Fibrosis–Related Diabetes and Self-Reported Ototoxicity Symptoms
Purpose: Persons with cystic fibrosis (PwCF) are at high risk for ototoxicity due to the routine use of intravenous aminoglycoside (IV-AG) antibiotics in respiratory infection management. Additionally, factors that contribute to ototoxicity-related symptom development and severity in PwCF are unknown. Given the increased risk of ototoxicity in people with diabetes, we explored the association between cystic fibrosis–related diabetes (CFRD) and self-reported ototoxicity symptoms (tinnitus and vestibular problems) in PwCF treated with aminoglycosides. Method: PwCF ( N = 39; 25 females, 14 males; M age = 30.1 years, SD = 10.3) were recruited from the Cystic Fibrosis Care Center at Oregon Health & Science University. Patients completed the validated questionnaires to ascertain their experiences with ototoxicity-related symptoms of tinnitus and balance function. The diagnosis of CFRD, including oral glucose tolerance testing (OGTT), insulin treatment, hemoglobin A1c, and cumulative IV-AG treatment history, was obtained through a medical chart review. Participants were classified into three groups based on their medical diagnoses via OGTT: normal glucose tolerance (NGT; control; n = 16), abnormal glucose tolerance (AGT; n = 9), and CFRD ( n = 14). Participants in each group were further classified based on survey outcomes for ototoxicity-related symptoms. Results: There was a trend toward a higher proportion of patients with CFRD reporting tinnitus compared to the AGT and NGT groups, but did not meet statistical significance ( X 2 = 2.24, p = .13). Approximately, 43% of patients with CFRD reported experiencing clinically significant tinnitus lasting > 3 min compared to 11% in the AGT group and 13% in the NGT group ( X 2 = 3.751, p = .05). Cumulative IV-AG exposure tended to be higher in CFRD compared to other groups. High balance function was generally reported in all groups. Conclusions: Patients with CFRD have greater ototoxicity-related symptoms. Further investigation of the relationship between CF-related comorbidities and the risk of developing ototoxicity-related symptoms is warranted to improve the detection and management of ototoxicity in PwCF.
- 8 February 2024
- Published by American Speech Language Hearing Association in Perspectives of the Asha Special Interest Groups
- Vol. 9 (1) , 113-123
What's New in Ototoxicity Management?
Purpose: Ototoxic medications and chemical agents in the workplace can put individuals' hearing and vestibular health at risk for permanent injury. Proactive ototoxicity management (OtoM) strategies aim to minimize exposure, avoid onset of symptoms, provide ongoing monitoring, and manage auditory and vestibular changes as the clinical needs of the patient evolve. During a 2021 American Speech-Language-Hearing Association Special Interest Groups Open House, members of the International Ototoxicity Management Group discussed how best to integrate OtoM into routine clinical practice, what tools to use, and what special considerations need to be understood to best support patients and their families. Here, we have summarized their viewpoints to encourage widespread adoption of improved OtoM services for at-risk individuals. Conclusions: The field of audiology needs to move to a place where we better understand the full extent of ototoxicity and can agree on expanding minimum guidelines that can be implemented more universally to mitigate, detect, and manage the damage from ototoxic exposures. Only recently has our field seen a therapeutic drug that can protect against ototoxicity; however, the population served is restricted only to children receiving treatment for nonmetastatic carcinoma. This is hopefully just the beginning of future therapeutic interventions to come, but, in the meantime, ototoxicity resulting from other medications in different patient populations and chemical agents persists.
- 8 February 2024
- Published by American Speech Language Hearing Association in Perspectives of the Asha Special Interest Groups
- Vol. 9 (1) , 113-123
What's New in Ototoxicity Management?
Purpose: Ototoxic medications and chemical agents in the workplace can put individuals' hearing and vestibular health at risk for permanent injury. Proactive ototoxicity management (OtoM) strategies aim to minimize exposure, avoid onset of symptoms, provide ongoing monitoring, and manage auditory and vestibular changes as the clinical needs of the patient evolve. During a 2021 American Speech-Language-Hearing Association Special Interest Groups Open House, members of the International Ototoxicity Management Group discussed how best to integrate OtoM into routine clinical practice, what tools to use, and what special considerations need to be understood to best support patients and their families. Here, we have summarized their viewpoints to encourage widespread adoption of improved OtoM services for at-risk individuals. Conclusions: The field of audiology needs to move to a place where we better understand the full extent of ototoxicity and can agree on expanding minimum guidelines that can be implemented more universally to mitigate, detect, and manage the damage from ototoxic exposures. Only recently has our field seen a therapeutic drug that can protect against ototoxicity; however, the population served is restricted only to children receiving treatment for nonmetastatic carcinoma. This is hopefully just the beginning of future therapeutic interventions to come, but, in the meantime, ototoxicity resulting from other medications in different patient populations and chemical agents persists.
- 11 October 2021
- Published by American Speech Language Hearing Association in American Journal of Audiology
- Vol. 30 (3S) , 870-886
A Randomized Controlled Trial Using Automated Technology for Improving Ototoxicity Monitoring in VA Oncology Patients
Purpose: Determine the efficacy of ototoxicity monitoring (OM) administered as automated protocols with the Oto-ID mobile audiometer (automated ototoxicity monitoring [A-OM]), compared with usual care (UC) OM in cancer patients receiving cisplatin. Method: Participants were patients ( n = 46, mean age 64.7 years; range: 30–78 years) receiving cisplatin-based chemotherapy at the Department of Veterans Affairs Portland Health Care System. A randomized controlled trial contrasted A-OM and UC at up to three program evaluations (PEs) conducted by the study audiologist who was blinded to arm through PE1. PE1 occurred before randomization or oncology treatment; PE2 and PE3 occurred during and/or after treatment at 35 and 365 days postrandomization. The A-OM group ( n = 24) used Oto-ID to screen their hearing before each cisplatin dose. Oto-ID results were sent to the study audiologist for interpretation, follow-up, and care coordination. The UC group ( n = 22) received a consult for OM services through the audiology clinic. Outcomes included hearing shift near each patient's high-frequency hearing limit, revised hearing-handicap inventory score, and survival time from the start of treatment. Adherence to OM protocols, patients' use of aural rehabilitation services, and oncologists' treatment decisions were also examined. Results: Ototoxicity was identified at a high overall rate (46% and 76% at 35 and 365 days, respectively, postrandomization). Adherence to monitoring prior to each cisplatin dose was 83.3% for those randomized to A-OM compared with 4.5% for UC. Randomization to A-OM was not associated with reduced ototoxic hearing shifts or self-reported hearing handicap relative to UC; neither did it compromise participants' survival. Half of participants in each arm accessed aural rehabilitation services. One in each arm had a documented ototoxicity-related cisplatin dose reduction. Conclusions: Auditory impairment was an actionable concern for the participants and their oncology providers. A dedicated surveillance program using the Oto-ID's automated protocols improved adherence to OM recommendations over a traditional UC service delivery model. Supplemental Material: https://doi.org/10.23641/asha.16649602
- 11 October 2021
- Published by American Speech Language Hearing Association in American Journal of Audiology
- Vol. 30 (3S) , 870-886
A Randomized Controlled Trial Using Automated Technology for Improving Ototoxicity Monitoring in VA Oncology Patients
Purpose: Determine the efficacy of ototoxicity monitoring (OM) administered as automated protocols with the Oto-ID mobile audiometer (automated ototoxicity monitoring [A-OM]), compared with usual care (UC) OM in cancer patients receiving cisplatin. Method: Participants were patients ( n = 46, mean age 64.7 years; range: 30–78 years) receiving cisplatin-based chemotherapy at the Department of Veterans Affairs Portland Health Care System. A randomized controlled trial contrasted A-OM and UC at up to three program evaluations (PEs) conducted by the study audiologist who was blinded to arm through PE1. PE1 occurred before randomization or oncology treatment; PE2 and PE3 occurred during and/or after treatment at 35 and 365 days postrandomization. The A-OM group ( n = 24) used Oto-ID to screen their hearing before each cisplatin dose. Oto-ID results were sent to the study audiologist for interpretation, follow-up, and care coordination. The UC group ( n = 22) received a consult for OM services through the audiology clinic. Outcomes included hearing shift near each patient's high-frequency hearing limit, revised hearing-handicap inventory score, and survival time from the start of treatment. Adherence to OM protocols, patients' use of aural rehabilitation services, and oncologists' treatment decisions were also examined. Results: Ototoxicity was identified at a high overall rate (46% and 76% at 35 and 365 days, respectively, postrandomization). Adherence to monitoring prior to each cisplatin dose was 83.3% for those randomized to A-OM compared with 4.5% for UC. Randomization to A-OM was not associated with reduced ototoxic hearing shifts or self-reported hearing handicap relative to UC; neither did it compromise participants' survival. Half of participants in each arm accessed aural rehabilitation services. One in each arm had a documented ototoxicity-related cisplatin dose reduction. Conclusions: Auditory impairment was an actionable concern for the participants and their oncology providers. A dedicated surveillance program using the Oto-ID's automated protocols improved adherence to OM recommendations over a traditional UC service delivery model. Supplemental Material: https://doi.org/10.23641/asha.16649602
- 3 October 2021
- Published by American Speech Language Hearing Association in American Journal of Audiology
- Vol. 30 (3S) , 797-799
Ototoxicity and Noise Damage: From Preclinical Findings to Audiological Management Introduction
- 3 October 2021
- Published by American Speech Language Hearing Association in American Journal of Audiology
- Vol. 30 (3S) , 797-799
Ototoxicity and Noise Damage: From Preclinical Findings to Audiological Management Introduction
- 22 September 2021
- Published by American Speech Language Hearing Association in American Journal of Audiology
- Vol. 30 (3S) , 800-809
Clinical Considerations for Routine Auditory and Vestibular Monitoring in Patients With Cystic Fibrosis
Purpose: Specific classes of antibiotics, such as aminoglycosides, have well-established adverse events producing permanent hearing loss, tinnitus, and balance and/or vestibular problems (i.e., ototoxicity). Although these antibiotics are frequently used to treat pseudomonas and other bacterial infections in patients with cystic fibrosis (CF), there are no formalized recommendations describing approaches to implementation of guideline adherent ototoxicity monitoring as part of CF clinical care. Method: This consensus statement was developed by the International Ototoxicity Management Working Group (IOMG) Ad Hoc Committee on Aminoglycoside Antibiotics to address the clinical need for ototoxicity management in CF patients treated with known ototoxic medications. These clinical protocol considerations were created using consensus opinion from a community of international experts and available evidence specific to patients with CF, as well as published national and international guidelines on ototoxicity monitoring. Results: The IOMG advocates four clinical recommendations for implementing routine and guideline adherent ototoxicity management in patients with CF. These are (a) including questions about hearing, tinnitus, and balance/vestibular problems as part of the routine CF case history for all patients; (b) utilizing timely point-of-care measures; (c) establishing a baseline and conducting posttreatment evaluations for each course of intravenous ototoxic drug treatment; and (d) repeating annual hearing and vestibular evaluations for all patients with a history of ototoxic antibiotic exposure. Conclusion: Increased efforts for implementation of an ototoxicity management program in the CF care team model will improve identification of ototoxicity signs and symptoms, allow for timely therapeutic follow-up, and provide the clinician and patient an opportunity to make an informed decision about potential treatment modifications to minimize adverse events. Supplemental Material: https://doi.org/10.23641/asha.16624366
- 22 September 2021
- Published by American Speech Language Hearing Association in American Journal of Audiology
- Vol. 30 (3S) , 800-809
Clinical Considerations for Routine Auditory and Vestibular Monitoring in Patients With Cystic Fibrosis
Purpose: Specific classes of antibiotics, such as aminoglycosides, have well-established adverse events producing permanent hearing loss, tinnitus, and balance and/or vestibular problems (i.e., ototoxicity). Although these antibiotics are frequently used to treat pseudomonas and other bacterial infections in patients with cystic fibrosis (CF), there are no formalized recommendations describing approaches to implementation of guideline adherent ototoxicity monitoring as part of CF clinical care. Method: This consensus statement was developed by the International Ototoxicity Management Working Group (IOMG) Ad Hoc Committee on Aminoglycoside Antibiotics to address the clinical need for ototoxicity management in CF patients treated with known ototoxic medications. These clinical protocol considerations were created using consensus opinion from a community of international experts and available evidence specific to patients with CF, as well as published national and international guidelines on ototoxicity monitoring. Results: The IOMG advocates four clinical recommendations for implementing routine and guideline adherent ototoxicity management in patients with CF. These are (a) including questions about hearing, tinnitus, and balance/vestibular problems as part of the routine CF case history for all patients; (b) utilizing timely point-of-care measures; (c) establishing a baseline and conducting posttreatment evaluations for each course of intravenous ototoxic drug treatment; and (d) repeating annual hearing and vestibular evaluations for all patients with a history of ototoxic antibiotic exposure. Conclusion: Increased efforts for implementation of an ototoxicity management program in the CF care team model will improve identification of ototoxicity signs and symptoms, allow for timely therapeutic follow-up, and provide the clinician and patient an opportunity to make an informed decision about potential treatment modifications to minimize adverse events. Supplemental Material: https://doi.org/10.23641/asha.16624366
- 24 July 2020
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 20 (2) , 278-283
Prospective cohort study of ototoxicity in persons with cystic fibrosis following a single course of intravenous tobramycin
- 24 July 2020
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 20 (2) , 278-283
Prospective cohort study of ototoxicity in persons with cystic fibrosis following a single course of intravenous tobramycin
- Open Access
Functional Impacts of Aminoglycoside Treatment on Speech Perception and Extended High-Frequency Hearing Loss in Cystic Fibrosis
Purpose: The purpose of this study is to better understand the prevalence of ototoxicity-related hearing loss and its functional impact on communication in a pediatric and young adult cohort with cystic fibrosis (CF) and individuals without CF (controls). Method: Observational, cross-sectional investigation of hearing function in children, teens, and young adults with CF (n = 57, mean = 15.0 yr.) who received intravenous aminoglycoside antibiotics and age- and gender-matched controls (n = 61, mean = 14.6 yr.). Participants completed standard and extended high frequency audiometry, middle ear measures, speech perception tests, and a hearing and balance questionnaire. Results: Individuals with CF were 3 to 4 times more likely to report issues with hearing, balance, and tinnitus and performed significantly poorer on speech perception tasks compared to controls. A higher prevalence of hearing loss was observed in individuals with CF (57%) compared to controls (37%). CF and control groups had similar proportions of slight and mild hearing losses, however individuals with CF were 7.6 times more likely to have moderate and greater degrees of hearing loss. Older participants displayed higher average EHF thresholds, with no effect of age on average SF thresholds. Although middle ear dysfunction has not previously been reported to be more prevalent in CF, this study showed that 16% had conductive or mixed hearing loss and higher rates of previous otitis media and pressure equalization (PE) tube surgeries compared to controls. Conclusions: Individuals with CF have a higher prevalence of conductive, mixed and sensorineural hearing loss, poorer speech-in-noise performance and higher rates of multiple symptoms associated with otologic disorders (tinnitus, hearing difficulty, dizziness, imbalance and otitis media) compared to controls. Accordingly, children with CF should be asked about these symptoms, receive baseline hearing assessment(s) prior to treatment with potentially ototoxic medications, and at regular intervals thereafter in order to provide otologic and audiologic treatment for hearing and ear-related problems to improve communication functioning.
Open AccessFunctional Impacts of Aminoglycoside Treatment on Speech Perception and Extended High-Frequency Hearing Loss in Cystic Fibrosis
Purpose: The purpose of this study is to better understand the prevalence of ototoxicity-related hearing loss and its functional impact on communication in a pediatric and young adult cohort with cystic fibrosis (CF) and individuals without CF (controls). Method: Observational, cross-sectional investigation of hearing function in children, teens, and young adults with CF (n = 57, mean = 15.0 yr.) who received intravenous aminoglycoside antibiotics and age- and gender-matched controls (n = 61, mean = 14.6 yr.). Participants completed standard and extended high frequency audiometry, middle ear measures, speech perception tests, and a hearing and balance questionnaire. Results: Individuals with CF were 3 to 4 times more likely to report issues with hearing, balance, and tinnitus and performed significantly poorer on speech perception tasks compared to controls. A higher prevalence of hearing loss was observed in individuals with CF (57%) compared to controls (37%). CF and control groups had similar proportions of slight and mild hearing losses, however individuals with CF were 7.6 times more likely to have moderate and greater degrees of hearing loss. Older participants displayed higher average EHF thresholds, with no effect of age on average SF thresholds. Although middle ear dysfunction has not previously been reported to be more prevalent in CF, this study showed that 16% had conductive or mixed hearing loss and higher rates of previous otitis media and pressure equalization (PE) tube surgeries compared to controls. Conclusions: Individuals with CF have a higher prevalence of conductive, mixed and sensorineural hearing loss, poorer speech-in-noise performance and higher rates of multiple symptoms associated with otologic disorders (tinnitus, hearing difficulty, dizziness, imbalance and otitis media) compared to controls. Accordingly, children with CF should be asked about these symptoms, receive baseline hearing assessment(s) prior to treatment with potentially ototoxic medications, and at regular intervals thereafter in order to provide otologic and audiologic treatment for hearing and ear-related problems to improve communication functioning.
- 1 January 2019
- Published by Elsevier in Hearing Research
- Vol. 371, 117-139
High frequency transient-evoked otoacoustic emission measurements using chirp and click stimuli
- 1 January 2019
- Published by Elsevier in Hearing Research
- Vol. 371, 117-139
High frequency transient-evoked otoacoustic emission measurements using chirp and click stimuli
- 1 January 2018
- Published by Wolters Kluwer Health in Ear & Hearing
- Vol. 39 (1) , 69-84
Chirp-Evoked Otoacoustic Emissions and Middle Ear Absorbance for Monitoring Ototoxicity in Cystic Fibrosis Patients
Objectives: The goal of this study was to investigate the use of transient-evoked otoacoustic emissions (TEOAEs) and middle ear absorbance measurements to monitor auditory function in patients with cystic fibrosis (CF) receiving ototoxic medications. TEOAEs were elicited with a chirp stimulus using an extended bandwidth (0.71 to 8 kHz) to measure cochlear function at higher frequencies than traditional TEOAEs. Absorbance over a wide bandwidth (0.25 to 8 kHz) provides information on middle ear function. The combination of these time-efficient measurements has the potential to identify early signs of ototoxic hearing loss. Design: A longitudinal study design was used to monitor the hearing of 91 patients with CF (median age = 25 years; age range = 15 to 63 years) who received known ototoxic medications (e.g., tobramycin) to prevent or treat bacterial lung infections. Results were compared to 37 normally hearing young adults (median age = 32.5 years; age range = 18 to 65 years) without a history of CF or similar treatments. Clinical testing included 226-Hz tympanometry, pure-tone air-conduction threshold testing from 0.25 to 16 kHz and bone conduction from 0.25 to 4 kHz. Experimental testing included wideband absorbance at ambient and tympanometric peak pressure and TEOAEs in three stimulus conditions: at ambient pressure and at tympanometric peak pressure using a chirp stimulus with constant incident pressure level across frequency and at ambient pressure using a chirp stimulus with constant absorbed sound power across frequency. Results: At the initial visit, behavioral audiometric results indicated that 76 of the 157 ears (48%) from patients with CF had normal hearing, whereas 81 of these ears (52%) had sensorineural hearing loss for at least one frequency. Seven ears from four patients had a confirmed behavioral change in hearing threshold for ≥3 visits during study participation. Receiver operating characteristic curve analyses demonstrated that all three TEOAE conditions were useful for distinguishing CF ears with normal hearing from ears with sensorineural hearing loss, with an area under the receiver operating characteristic curve values ranging from 0.78 to 0.92 across methods for frequency bands from 2.8 to 8 kHz. Case studies are presented to illustrate the relationship between changes in audiometric thresholds, TEOAEs, and absorbance across study visits. Absorbance measures permitted identification of potential middle ear dysfunction at 5.7 kHz in an ear that exhibited a temporary hearing loss. Conclusions: The joint use of TEOAEs and absorbance has the potential to explain fluctuations in audiometric thresholds due to changes in cochlear function, middle ear function, or both. These findings are encouraging for the joint use of TEOAE and wideband absorbance objective tests for monitoring ototoxicity, particularly, in patients who may be too ill for behavioral hearing tests. Additional longitudinal studies are needed in a larger number of CF patients receiving ototoxic drugs to further evaluate the clinical utility of these measures in an ototoxic monitoring program.
- 1 January 2018
- Published by Wolters Kluwer Health in Ear & Hearing
- Vol. 39 (1) , 69-84
Chirp-Evoked Otoacoustic Emissions and Middle Ear Absorbance for Monitoring Ototoxicity in Cystic Fibrosis Patients
Objectives: The goal of this study was to investigate the use of transient-evoked otoacoustic emissions (TEOAEs) and middle ear absorbance measurements to monitor auditory function in patients with cystic fibrosis (CF) receiving ototoxic medications. TEOAEs were elicited with a chirp stimulus using an extended bandwidth (0.71 to 8 kHz) to measure cochlear function at higher frequencies than traditional TEOAEs. Absorbance over a wide bandwidth (0.25 to 8 kHz) provides information on middle ear function. The combination of these time-efficient measurements has the potential to identify early signs of ototoxic hearing loss. Design: A longitudinal study design was used to monitor the hearing of 91 patients with CF (median age = 25 years; age range = 15 to 63 years) who received known ototoxic medications (e.g., tobramycin) to prevent or treat bacterial lung infections. Results were compared to 37 normally hearing young adults (median age = 32.5 years; age range = 18 to 65 years) without a history of CF or similar treatments. Clinical testing included 226-Hz tympanometry, pure-tone air-conduction threshold testing from 0.25 to 16 kHz and bone conduction from 0.25 to 4 kHz. Experimental testing included wideband absorbance at ambient and tympanometric peak pressure and TEOAEs in three stimulus conditions: at ambient pressure and at tympanometric peak pressure using a chirp stimulus with constant incident pressure level across frequency and at ambient pressure using a chirp stimulus with constant absorbed sound power across frequency. Results: At the initial visit, behavioral audiometric results indicated that 76 of the 157 ears (48%) from patients with CF had normal hearing, whereas 81 of these ears (52%) had sensorineural hearing loss for at least one frequency. Seven ears from four patients had a confirmed behavioral change in hearing threshold for ≥3 visits during study participation. Receiver operating characteristic curve analyses demonstrated that all three TEOAE conditions were useful for distinguishing CF ears with normal hearing from ears with sensorineural hearing loss, with an area under the receiver operating characteristic curve values ranging from 0.78 to 0.92 across methods for frequency bands from 2.8 to 8 kHz. Case studies are presented to illustrate the relationship between changes in audiometric thresholds, TEOAEs, and absorbance across study visits. Absorbance measures permitted identification of potential middle ear dysfunction at 5.7 kHz in an ear that exhibited a temporary hearing loss. Conclusions: The joint use of TEOAEs and absorbance has the potential to explain fluctuations in audiometric thresholds due to changes in cochlear function, middle ear function, or both. These findings are encouraging for the joint use of TEOAE and wideband absorbance objective tests for monitoring ototoxicity, particularly, in patients who may be too ill for behavioral hearing tests. Additional longitudinal studies are needed in a larger number of CF patients receiving ototoxic drugs to further evaluate the clinical utility of these measures in an ototoxic monitoring program.